Investing.comDoubao · 实盘可交易 · 做空市场:美股▲ 赚 +2.87% · 已结算把握 5/10
北京时间·🕒 发布 08:56:39·⟳ 抓取 08:57:19 +40s·⚡ 决策 10-21 09:01:07 +3m48s·6.7 天前
Disc Medicine折价5.6%、上调规模定价4.5亿美元增发，新股摊薄约15.6%，盘后仅微跌、次日开盘存补跌空间
折价5.6%、规模由3.5亿上调至4.5亿、完全摊薄约18%的生物科技增发构成直接公司级负面；消息盘后发布、夜盘成交极薄几乎未定价，次日开盘有补跌空间。但市场对19日已宣布发行有部分预期、75美元有承销商护盘且刚经历+39%强势上涨，edge中等，故仅以small仓位做空、严格限制追低。
📄 原文Investing.com↗ 原文
Disc Medicine prices $450 million stock offering at $75/share
WATERTOWN, Mass. - Disc Medicine Inc. (NASDAQ:IRON) priced an underwritten public offering of 6 million shares of commo…
▲ 赚 +2.87%入场 10-21 盘前首笔 @77.81 → 离场 10-22 常规开盘 @75.48
日 K 取自复盘打分切片 · 蓝点/蓝虚线 = 纸面入场价 · 灰虚线 = 纸面离场 · 持有期红底 = 赚(做空:价格在入场线下方)、绿底 = 亏
💡 交易逻辑折价5.6%增发摊薄15.6%，盘后未反应，博次日补跌
怎么做空 开盘做空 不低于昨收 -2%（低于下限不成交）
怎么平空 止盈 -5%(半仓)/-9%(清仓) · 止损 +7% · 时间止损 3日
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
分时走势
做空 IRON.US Disc Medicine
5 个交易日均已收盘,数据完整 · 美股含盘前盘后(灰底:美东 04:00 至收盘后 4 小时)
- 发布 10-21 08:56 北京(美东 10-20 20:56)
- 抓取 10-21 08:57 北京(美东 10-20 20:57)
- 决策 10-21 09:01 北京(美东 10-20 21:01)
- 入场 10-21 16:02 北京(美东 10-21 04:02) · 盘前首笔 @77.81
- 离场 10-22 21:30 北京(美东 10-22 09:30) · 常规开盘 @75.48
时间轴只含交易时段(午休、隔夜已压缩);横轴为北京时间,悬停看当地时间;蓝虚线 = 纸面入场价;建仓日图红线在昨收上方、绿线在下方
成交明细 · 纸面
做空 IRON.US Disc Medicine
| 收益状态 | +2.87% 已平仓 |
|---|---|
| 进场成交 | 2026-10-21 · 盘前首笔 · 10-21 16:02 北京 · @77.81 |
| 离场成交 | 2026-10-22 · 常规开盘 · @75.4801 |
| 毛收益 | +2.99% |
| 成本 | +0.12% |
| 净收益 | +2.87% |
| 计入收益 | +2.87% |
| 建仓日 | 2026-10-21 · 进场不早于新闻时刻 + 2 分钟 |
收益口径 event_time_plus_2min_10min_walk_open_topup_to_next_open_exchange_calendar_fill_model_local_notional_v9 · method_id m8db1cbc8f2d · 截至 2026-10-28 00:58
研究档案
结论摘要
Disc Medicine盘后以75美元定价4.5亿（最高5.18亿）增发，较收盘折价5.6%、摊薄约15.6%-18%，而夜盘仅微跌约0.8%且成交量极小，定价确认与上调规模尚未被消化，次日大概率低开补跌；但融资强化现金跑道、承销商护盘与前期强势上涨限制幅度，故小仓SHORT_AT_OPEN并限制追空。
消息传播链
- 节点
- 节点
关键理由
- 按当前约38.4百万股本计算，600万新股摊薄约15.6%、含绿鞋约18%，且发行规模由3.5亿上调至4.5亿，供给冲击与折价信号明确
- 定价在盘后20:52 ET公布，盘后/夜盘合计成交约20万股、价格仅反映约-0.8%至-1.0%，远未消化折价与摊薄，10月21日常规开盘存在补跌窗口
主要风险
- 10月19日+38.9%疑似由bitopertin临床/商业化正面催化驱动，若利好逻辑延续，增发后现金跑道延长反而可能被市场视为消除融资不确定性，股价不跌反涨
- 承销商通常在发行价75美元附近护盘（仅约5.6%下行空间），若开盘大幅低开后迅速获承接，做空空间有限且易被逼空
反向证据
- 做空前查反向 · 来源 web · 日期 2026-10-20 · 影响 weakens
10月19日IRON单日+38.86%，同期宣布发行，疑似存在bitopertin临床/监管正面催化；若基本面利好强劲，增发摊薄可被快速消化，削弱做空逻辑
检索:Disc Medicine bitopertin clinical data catalyst October 2026 offering upsized 原文 ↗ - 做空前查反向 · 来源 web · 日期 2026-10-20 · 影响 weakens
4.5亿募资明确用于bitopertin商业化准备与研发，显著延长临床期公司现金跑道，可能被多头解读为消除未来融资风险
检索:Disc Medicine cash runway balance sheet 2026 原文 ↗
先例如何影响了这次决策
对本次决策的影响:先例仅确认做空方向、不足以给激进幅度，因此仓位压至small、目标仅5%-9%、并设置开盘低开超6%即放弃的追空限制
方向:检索到Larimar、Dyne、Crescent、Nuvectis、Nuvation等多起2026年生物科技upsized/折价增发定价后股价当日下跌的案例（Nasdaq/RTTNews标题即标注Stock Down），方向上支持增发定价后短期走弱，但这些链接为转载/聚合稿且未逐篇取得一手首发与精确时刻，不满足首发锚要求，故未喂入event_study
涨幅量级:无干净的同市场对齐先例，无法可靠校准次日缺口与tp/sl幅度；仅依据折价深度（5.6%）、摊薄比例（约15.6%）和承销商护盘位（75美元）做保守的5%-9%目标设定
形态:生物科技折价增发定价后首日普遍低开承压，但发行成功+现金跑道延长常使跌幅在发行价附近企稳，未见可靠的持续崩盘点状证据
工具执行结果 · 成功 5 · 降级 0 · 失败 0 · 取消 0
- search_processed_events 成功 stock_tools HTTP · 10 ms
{"result": "search_processed_events:agent query=`disc medicine 6 million shares follow-on offering priced | disc medicine iron 450 million stock offering 75 per share | iron bitopertin public offering underwritten 2026`；结构化索引覆盖完整 72 小时；旧记录兼容扫描近 0.0/72 小时、0 条本臂决策(完整)，返回 0 条候选。未命中只表示这些 agent query 表达式 - stock_quote 成功 stock_tools HTTP · 91 ms
{ - web_search 成功 doubao_search · 1,216 ms
豆包搜索结果（原始查询:Disc Medicine IRON stock offering $75 October 20 2026 closing price announcement；API SearchType:web） - web_search 成功 doubao_search · 1,215 ms
豆包搜索结果（原始查询:biotech upsized follow-on offering priced discount stock reaction next day clinical-stage 2025 2026；API SearchType:web） - validate_order 成功 stock_tools HTTP · 11 ms
{
原文全文
展开原文 · 1,922 字
WATERTOWN, Mass. - Disc Medicine Inc. (NASDAQ:IRON) priced an underwritten public offering of 6 million shares of common stock at $75.00 per share, according to a press release statement issued Tuesday.
The clinical-stage biopharmaceutical company granted underwriters a 30-day option to purchase up to 900,000 additional shares at the public offering price, less underwriting discounts and commissions. The aggregate gross proceeds are expected to reach $450 million before deducting underwriting discounts, commissions and other offering expenses, assuming the underwriters do not exercise their option.
The offering is expected to close on Friday, subject to customary closing conditions.
Disc Medicine stated it intends to use the net proceeds, together with existing cash, cash equivalents and marketable securities, to fund research and clinical development of current or additional product candidates. The company also plans to support potential commercialization of bitopertin for erythropoietic protoporphyria and X-linked protoporphyria, along with pre-commercialization activities for other product candidates. The remainder will be allocated to working capital and general corporate purposes.
Jefferies, Leerink Partners, Morgan Stanley and Cantor are serving as joint book-running managers for the offering. LifeSci Capital, BMO Capital Markets and H.C. Wainwright & Co. are acting as co-managers.
The offering is being conducted pursuant to an automatic shelf registration statement on Form S-3 filed with the Securities and Exchange Commission on August 8, 2024.
Disc Medicine focuses on discovering and developing treatments for patients with hematologic diseases, targeting fundamental biological pathways of red blood cell biology.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
Disc Medicine prices $450 million stock offering at $75/share
The clinical-stage biopharmaceutical company granted underwriters a 30-day option to purchase up to 900,000 additional shares at the public offering price, less underwriting discounts and commissions. The aggregate gross proceeds are expected to reach $450 million before deducting underwriting discounts, commissions and other offering expenses, assuming the underwriters do not exercise their option.
The offering is expected to close on Friday, subject to customary closing conditions.
Disc Medicine stated it intends to use the net proceeds, together with existing cash, cash equivalents and marketable securities, to fund research and clinical development of current or additional product candidates. The company also plans to support potential commercialization of bitopertin for erythropoietic protoporphyria and X-linked protoporphyria, along with pre-commercialization activities for other product candidates. The remainder will be allocated to working capital and general corporate purposes.
Jefferies, Leerink Partners, Morgan Stanley and Cantor are serving as joint book-running managers for the offering. LifeSci Capital, BMO Capital Markets and H.C. Wainwright & Co. are acting as co-managers.
The offering is being conducted pursuant to an automatic shelf registration statement on Form S-3 filed with the Securities and Exchange Commission on August 8, 2024.
Disc Medicine focuses on discovering and developing treatments for patients with hematologic diseases, targeting fundamental biological pathways of red blood cell biology.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
Disc Medicine prices $450 million stock offering at $75/share
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
a1a8c23b59· 2026-10-21 09:01 · doubao / doubao-seed-evolving-latest-version · 策略包658c0c1e2ba5当前